Biotech Values

[DewDiligence]

GRAY reverse-merges with—(private)—CalciMedica:

https://www.globenewswire.com/news-release/2022/11/21/2560379/0/en/Graybug-and-CalciMedica-Enter-into-Definitive-Merger-Agreement.html

Graybug Vision, Inc. and CalciMedica Inc. today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on further developing CalciMedica’s lead product candidate Auxora, a proprietary, intravenous-formulated, small molecule calcium-release activated calcium (CRAC) channel inhibitor, to treat life-threatening inflammatory diseases, such as acute pancreatitis (AP), asparaginase-associated pancreatitis (AAP), acute kidney injury (AKI), and acute hypoxemic respiratory failure (AHRF), for which there are no currently approved therapies.

…Graybug equity holders are expected to collectively own approximately 29% of the combined company, and pre-merger CalciMedica equity holders are expected to collectively own approximately 71%...

GRAY was +19% in AH trading on Monday but, even after that pop, the share price is down 93% from its 2020 IPO (#msg-158528937).